Ken Griffin Compugen LTD Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$1.56 - $2.1 $8,892 - $11,970	-5,700 Reduced 30.98%	12,700 $22,000
Q2 2024 Aug 14, 2024	SELL	$1.68 - $2.52 $168 - $252	-100 Reduced 0.54%	18,400 $30,000
Q1 2024 May 15, 2024	BUY	$1.75 - $2.95 $8,400 - $14,160	4,800 Added 35.04%	18,500 $47,000
Q4 2023 Feb 14, 2024	BUY	$0.53 - $2.0 $1,378 - $5,200	2,600 Added 23.42%	13,700 $27,000
Q3 2023 Nov 14, 2023	BUY	$0.88 - $1.31 $4,664 - $6,943	5,300 Added 91.38%	11,100 $10,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.38 $3,305 - $8,003	5,800 New	5,800 $6,000
Q4 2022 Feb 14, 2023	BUY	$0.58 - $1.2 $57 - $120	100 New	100 $0

13.1M

79.2K

12.7K

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $122M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.